| Name | CITCO |
| Description | CITCO inhibits growth and expansion of brain tumour stem cells (BTSCs) and has an EC50 of 49 nM over pregnane X receptor (PXR), and no activity on other nuclear receptors. CITCO is an imidazothiazole derivative and it also is a selective Constitutive androstane receptor (CAR) agonist. |
| In vitro | CITCO (1-50 μM; 48 hours) results in dose-dependent inhibition of viable cell count and proliferation in T98G, U87MG glioma, and BTSCs. CITCO (0-25 μM; 48 hours) significantly increases CAR protein expression in T98G, U87MG glioma, and BTSCs. CITCO (2.5-10 μM; 48 hours) induces apoptosis in BTSCs in a dose-dependent manner, but not in normal astrocytes. CITCO (2.5, 5 μM; 48 hours) induces differential cell cycle arrest in various BTSCs in culture, but not in normal astrocytes[1]. |
| In vivo | CITCO (intraperitoneal; 25?μg; on days 22, 24, 26, 30 and 36) results a significant decrease in tumour growth. After treatment with 100?μg CITCO, it further decreases to an undetectable level [1]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : insoluble
DMSO : 11 mg/ml (25.19 mM)
|
| Keywords | CITCO | Inhibitor | inhibit | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
| Related Compound Libraries | Apoptosis Compound Library | Nuclear Receptor Compound Library | Bioactive Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
